KİŞİSEL BİLGİLER Ad-Soyad Kurum İletişim E-posta Posta Adresi İş Adresi Doğum Tarihi Doğum Yeri Medeni Hali Yabancı Dili Prof. Dr. Ahmet Muzaffer DEMİR Trakya Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı Hematoloji Bilim Dalı Öğretim Üyesi Hast: 0284/235 10 41; Ev: 0284/226 11 21 Faks: 0284/235 10 41 mdemir@trakya.edu.tr ; muzdem001@gmail.com Demirkapı Mevkii, E-5 Karayolu Arseven Sitesi No:32/9, 22030, Edirne Trakya Üniv. Tıp Fak. İç Hastalıkları AD Hematoloji BD 22030, Edirne 11 Şubat 1965 Suruç, Şanlıurfa Evli, 1 çocuk babası İngilizce EĞİTİM 1969 1974 1974 1977 1977 1980 1981 1987 1987 1992 1994 1997 1995 1995 (4 ay) 1999 2001 Atatürk İlkokulu, Suruç-Şanlıurfa (birincilik derecesi ile) Suruç Ortaokulu, Suruç-Şanlıurfa (birincilik derecesi ile) Suruç Lisesi, Suruç-Şanlıurfa (birincilik derecesi ile) İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi (İkincilik derecesi ile) İç Hastalıkları Uzmanlığı, Trakya Üniversitesi Tıp Fakültesi Hematoloji Yandal Uzmanlığı, Trakya Üniversitesi Tıp Fakültesi Hematoloji Yan Dal Eğitim Rotasyonu, İ.Ü. Cerrahpaşa Tıp Fakültesi Hemostaz-Tromboz Post-Doctoral Fellow, Loyola University Chicago, Medical Center IL, USA 1
ÇALIŞTIĞI KURUMLAR VE ÜNVANLARI 1987 1992 1992 1994 1993 1993 1994 1997 1997 1999 1999 2001 2001 2002 2003 2003 (2 ay) 2002 2007 18.07.2007-halen İç Hastalıkları Araştırma Görevlisi, Trakya Üniv. Tıp Fakültesi İç Hastalıkları Uzmanı, Edirne Devlet Hastanesi (Zorunlu Hizmet) Kütahya Hava er Eğitim Tugayı, 100 Yataklı Asker Hastanesi, Kısa Dönem Askerlik Hizmeti Hematoloji Yan Dal Uzmanlık Öğrencisi, Trakya Üniv. Tıp Fakültesi Yard. Doç. Dr., Hematoloji BD, Trakya Üniv. Tıp Fakültesi Hemostaz-Tromboz Fellow u, Loyola Univ. Chicago, Medical Center, IL, USA Yard. Doç. Dr., Hematoloji BD, Trakya Üniv. Tıp Fakültesi Visiting Professor, Kanser ve tromboz konusunda araştırma amaçlı Loyola Univ. Chicago, Medical Center, IL, USA Doç. Dr., Hematoloji BD, Trakya Üniv. Tıp Fakültesi Prof. Dr., Hematoloji Bilim Dalı Öğretim Üyesi ve Başkanı İDARİ GÖREVLER 1997 1999 2001 2004 1997 1999 1998 1999 2002 2003 2003 2004 Başhekim Yardımcılığı (Laboratuvarlar ve Eczane Koordinatörü) Başhekim Yardımcılığı (Laboratuvarlar ve Eczane Koordinatörü) Kan Bankası Sorumlu Doktoru, Trakya Üniversitesi Hastanesi Dönem III Eğitim Koordinatör yardımcısı Dönem IV Eğitim Koordinatörü Dönem IV Eğitim Koordinatörü 2
2002 2005 2002 2005 2002 2004 2003 2005 2003 2004 2005 Halen 2007 2009 2008-2009 2008-2011 2007-2009 2007-2015 2007-2015 2010-2015 2010-2015 2007-2013 Fakülte Kurulu Doçent Üyeliği T.Ü. Tıp Fakültesi Dergisi Editör Yardımcılığı Trakya Üniv. Atama ve Kalite Artırımı Komitesi Başkan Yardımcılığı Trakya Üniv. Hastanesi Acil Servis Başkan Yardımcılığı Trakya Üniversitesi Döner Sermaye Yürütme Kurulu Üyesi Hematoloji Bilim Dalı Başkanlığı Ders Kurulu VIII Başkan Yardımcısı Dönem III Eğitim Koordinatörlüğü Fakülte Kurulu Profesör Üyeliği Sağlık Bilimleri Enistitüsü İmmünoloji Anabilim Dalı Kurucu öğretim üyesi Kan Merkezi Müdürü, Trakya Üniversitesi Hastanesi Transfüzyon Komitesi Başkanı Terapötik Aferez Merkezi Sorumlusu, Trakya Üniversitesi Hastanesi Transfüzyon Merkezi Müdürü Merkez Laboratuvarı Hematoloji Bölümü Sorumlusu BİLİMSEL KURULUŞLARA ÜYELİKLER Ulusal Dernekler Türk Hematoloji Derneği 2015-2017 Dönemi Yönetim Kurulu Başkanı 2011-2013 Dönemi Yönetim Kurulu Üyesi ve Genel Sekreteri 2009-2011 Dönemi Yönetim Kurulu Üyesi ve Araştırma sekreteri Hemostaz ve Tromboz Alt Komitesi Genel Sekreterliği 2002 2004 3
Hemostaz ve Tromboz Alt Komite Başkanlığı 2004 2006 Hemofili BAK Başkanlığı 2010-2014 Dönemi 36, 37, 38, 30, 40, 41. Ulusal Hematoloji Kongrelerisi, Kongre Sekreteri 4., 5. International Congress on Leukemia, Lymphoma, Myeloma, Kongre Sekreteri 7 ve 8. Kemik iliği tansplantasyonu ve Hücresel tedaviler kongresi, Kongre sekreteri Tromboz, Hemostaz ve Anjiyoloji Derneği Yönetim Kurulu Başkanlığı, 2012-2014 Genel Sekreterliği, 2002 2004 Yönetim Kurulu Üyeliği, 2002 2004, 2006 2008, 2008 2010 Dernek Başkanı, 2014 2016 Türk İç Hastalıkları Uzmanlık Derneği Eğitim Komisyonu Üyesi Kan Merkezleri ve Transfüzyon Derneği Fleboloji Derneği Marmara Hemofili Derneği, Yönetim Kurulu Üyesi Hemofili Federasyonu (HEDEF) Yönetim Kurulu Üyesi Uluslararası Dernekler ISTH - International Society of Thrombosis and Hemostasis European Haematology Association American Society of Hematology American Society of Angiology, Fellow International Union of Angiology North America Thrombosis Forum, Fellow International Academia of Clinical Applied Thrombosis and Hemostasis, Fellow 4
The Mediterranean League Against Thromboembolic Diseases Scientific Committee Türkiye Temsilcisi 2016 ICT Congress President YAYIN KURULU VEYA YAYIN DANIŞMA KURULU ÜYELİKLERİ o Clinical/Applied Thrombosis and Hemostasis, Mediterreanean Editor o SCI de yer alan B grubu dergi, 2004 - halen devam etmektedir. o Turkish Journal of Hematology o Editör Yardımcısı, 2009-2015 o Yayın Danışma Kurulunda, o Hematolog Derleme Dergisi, Editör 2015-2017 o Trakya Üniversitesi Tıp Fakültesi Dergisi Editör Yardımcılığı 2002-2005 o Konuk Editör o PROSPECT DERGİSİ 5;2, Mayıs 2003 Antitrombotik Tedavi isimli ek sayıda o Hematolog Derleme Dergisi 2014;4(39): o Türkiye Klinik Bilimler Dergisi, Yayın Danışma Kurulunda, o Hematoloji-Türkiye Klinik Bilimler Dergisi, Yayın Danışma Kurulunda, o Uluslararası Hematoloji Onkoloji Dergisi, Yayın Danışma Kurulunda, o Fleboloji Dergisi o Turkish Journal of Pediatric Biochemistry HAKEMLİK GÖREVİ o Clinical/Applied Thrombosis and Hemostasis o Abstract reviewer-antithrombotic session American Society of Hematology, 50 th Annual Meeting and Exposition, December 6-9 2008 San Francisco, California o Cancer Resrearch o Thrombosis Research o Türk Hematoloji Dergisi o Trakya Üniversitesi Tıp Fakültesi Dergisi o Türkiye Klinik Bilimler Dergisi o Hematoloji-Türkiye Klinik Bilimler Dergisi o Uluslararası Hematoloji Onkoloji Dergisi 5
AKADEMİK JÜRİ ÜYELİKLERİ Doçentlik Atama Jüri Üyeliği Doçentlik Sıınav Jüri Üyeliği Profesörlük Atama Jüri Üyeliği Doç. Dr. Mustafa Oran, Namık Kemal Üniveritesi, 2015 Doç. Dr. Sernaz Uzunoğlu, Trakya Üniversitesi Doçentlik Ataması, Nisan 2014 Doç. Dr. Ramazan Esen, Van Yüzüncü Yıl Üniversitesi Doçentlik Ataması, Ocak 2014 Doç. Dr. İrfan Çiçin, 2010 Doç. Dr. Sami Kartı, 2009 Doç. Dr. Burhan Turgut, 2008 Doç. Dr. Figen Noyan Atalay, 2015 Doç. Dr. Muzaffer Keklik, 2015 Doç. Dr. Tülay Özçelik, 2010 Doç. Dr. Mehmet Ali Erkut, 2010 Doç. Dr. Ali Özdemir, 2008 Doç. Dr. Alp Günay, 2008 Doç. Dr. Funda Türkmen, 2008 Doç. Dr. Refik Demirtunç, 2008 Prof. Dr. İrfan Çiçin, Trakya Üniversitesi, 2015 Prof. Dr. Filiz Vural, Ege Üniversitesi, Mayıs 2015 Prof. Dr. Aynur Uğur Bilgin, Yüksek İhtisas Üniversitesi, Temmuz 2015 Prof. Dr. Sibel Güldiken, Trakya Üniversitesi, 2014 Prof. Dr. Mehmet Sönmez, Karadeniz Teknik Üniversitesi, 2014 Prof. Dr. Burhan Turgut, Namık Kemal Üniversitesi, Mayıs 2013 Prof. Dr. Gülsüm Emel Pamuk, Trakya Üniversitesi, 2013 Prof. Dr. Mutlu Arat, İstanbul Bilim Üniversitesi, 2013 Prof. Dr. Reyhan Diz-Küçükkaya, İstanbul Bilim Üniversitesi, 2013 Prof. Dr. Burhan Ferhanoğlu, Koç Üniversitesi, Aralık 2012 ÖDÜLLER o İ.Ü. Cerrahpaşa Tıp Fakültesi Mezuniyet Derecesi (İkincilik), 1987 o Trakya Üniversitesi Bilim ve Özendirme Ödülü, 2003 o Türk Hematoloji Derneği 2004 Yılı Klinik Bilimlerde En İyi Araştırma Ödülü Çetin M, Büyükberber S, Demir M, Sarı İ, Sarı İ, Deniz K, Camcı C, Öztürk A, Ünal A. Multipl Miyelomda siklooksigenaz ekspresyonunun prognoz ve yaşam süresi ile ilişkisi. Turk J Haematol 2004;21(3):O59 6
o Türk Hematoloji Derneği 2006 Yılı Endüstri Dalında En İyi Araştırma Ödülü Turgut B, Vural Ö, Pala FS, Pamuk GE, Tapakçıoğlu K, Gürkan H, Demir M, Algüneş Ç. Kronik Lenfositer Lösemi Hücrelerinin Sitogenetik ve Biyolojik Özellikleri ile In Vitro Spontan ve Fludarabine Bağlı Apotozisleri Arasındaki İlişkinin İncelenmesi. Türk Hematoloji Derneği 32. Ulusal Kongresi, Antalya, Turk J Haematol 2006; 23(Suppl 1):54 Sözel Bildiri#S0031 o EHA Travel Grant, 2005 Pamuk GE, Vural Ö, Turgut B, Demir M, Ümit H, Tezel A. The association of inflammatory response with the endothelium, platelets and the coagulation system in patients with ulcerative colitis. 10th Congress of the European Hematology Association, Stockholm, Sweden, Haematologica/the Hematology Journal, Volume 90, (Suppl. 2), p132, Abstract#0335, 2005. o EHA Travel Grant, 2006 Pamuk GE, Turgut B, Pamuk ON, Demir M, Cakir N. Increased platelet-monocyte and plateletneutrophil complex formation in primary raynaud phenomenon and in raynaud phenomenon secondary to systemic sclerosis. 11th Congress of the European Hematology Association, Amsterdam, the Netherlands, Haematologica/the Hematology Journal, Volume 91, (Suppl. 1), p339, Poster#0927, 2006. o Türk Hematoloji Derneği, En iyi Klinik Hematoloji Ödülü, 34. Ulusal Hematoloji Kongresi, Çeşme-İzmir Pamuk GE, Örüm H, Pamuk ÖN, Demir M, Turgut B, Çakır N. Yüksek trombosit-lökosit kompleks düzeyleri Behçet hastalığı büyük dammar tutulumunda rol oynuyor olabilir mi? o Türk Hematoloji Derneği, En Güzel Türkçe Bildiri Ödülü, 34. Ulusal Hematoloji Kongresi, Çeşme-İzmir Demir V, Demir M, Çiçin İ, Pamuk GE, Örüm H, Öztürk E, Çağlar T. İleri evre küçük hücreli dışı akciğer kanserinde anjiogenik antianjiogenik dengenin sağkalım sürelerine etkileri. o Türk Hematoloji Derneği, Genç Katılımcı Ödülü, 34. Ulusal Hematoloji Kongresi, Çeşme-İzmir Tekgündüz E, Kömürcü Y, Öztürk E, Pamuk GE, Özpuyan F, Turgut B, Demir M. Pediatrik kemoterapi protokolü ile tedavi edilen gençerişkin akut lenfoblastik lösemi olgularımızın değerlendirilmesi, 2008. 7
o 8. Medikal-Cerrahi Endokrinoloji Mezuniyet Sonrası Eğitim kursu Aydın Boysal Poster Ödülü" Sezer A, Tuncbilek N, Guldiken S, Demir M, Irfanoglu ME, Ibis C. The Risk Assessment of Venous Thromboembolism in Thyroid Surgery.5-8 Kasım 2009, Kuşadası o Pamuk GE, Uyanık MS, Akker M, Demir M. The clinical features of 105 CLL patients followed up at a single center. 3rd International Congress on LLM 11-14 May 2011, P018; Best Abstract Award YAPTIĞI TEZLER o İç Hastalıkları Uzmanlık Tezi Kansere Bağlı Kronik Hastalıklar Anemisinde Eritropoietin Düzeyleri, 1992 Tez yöneticisi: Prof. Dr. Özden Vural o Hematoloji Yan Dal Uzmanlık Tezi Venöz ve Arteriyel Trombozlu Olgularda Doğal İnhibitörler ve Aktive Protein C Direnci, 1997, Tez yöneticisi: Prof. Dr. Özden Vural YÖNETİLEN UZMANLIK TEZLERİ İç Hastalıkları Uzmanlık Tez Danışmalığı Dr. Türker Kundak, Edirne İli Merkezinde von Willebrand Hastalığı Taraması, 2002 2004 Dr. Nesibe Karahan, Normal gebelik seyrinde ve lohusallıkta fibrinolitik system inhibisyonunda TAFI ve TAFIa nın rolü, 2002-2006 Dr. Volkan Demir, Akciğer kanserli olgularda VEGF ve TF4 düzeylerinin yaşam süresi ve tromboz oluşumuna etkileri, 2006-2008. Dr. Meriç Şafak Özgenel, Varfarine bağlı kanamalarda risk faktörlerinin saptanması 2010 8
Dr. Çiğdem Kaptan Dahili yoğun bakım hastalarının periferik kanında eritroblastların varlığının saptanması ve bunun yaşam süresine etkisi, 2009 Dr. Yakup Bozyaka Trakya Üniversitesi Terapötik aferez sonuçlarının değerlendirilmesi, 2012 Dr. Yusuf Şapuk 2008-2012 Yılları arasında Trakya Üniversitesi Tıp Fakültesi Hematoloji Kliniğinde Hematolojik Habis Hastalık Tanısı ile Takip edilen hastaların demografik özelliklerin incelenmesi, 2015 Dr. Ahmet Küüçükarda Trakya Üniversitesi Hastanesi veri tabanındaki protein elektroforezlerinin değerlendirilmesi, 2015 Dr. Hasan Göze İç Hastalıkları kliniğinde yatan hastaların geriatrik değerlendirmesi, 2015 Yan Dal Uzmanlık Tez Danışmalığı Uzm. Dr. Emre Tekgündüz, Koroner anjiografisi normal olan geçirilmiş akut koroner sendromlu olgularda yapışkan Trombosit Sendromunun yeri, 2009 Uzm. Dr. Erman Öztürk, Non-Hodgkin Lenfomalarda COX-1 proteininin yaşam süresine etkisi, 2009 Uzm. Dr. Onur Kırkızlar, Kronik Miyeloid Lösemi olgularımızın geriye dönük değerlendirmesi, 2012 PROJELERDE YAPTIĞI GÖREVLER Proje Yürütücüsü 1. Kırklareli İl Genelinde Beta-Talasemi Taşıyıcılığı ve Anormal Hemoglobin Taranması, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-180, 1998 2. Tekirdağ İl Genelinde Hb A2 si yüksek β Talasemi Taşıyıcı Sıklığı ve Anormal Hemoglobin Taraması, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP 275, 1999 9
3. Heparine-bağlı immun trombositopeni sıklığının saptanması, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP 498, 2003-2006 4. Edirne İl Merkezinde von Willebrand Hastalığı Sıklığının Saptanması, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP 536, 2002 2004 5. Normal Seyirli Gebelikte Fibrinolitik Sistem Parametreleri ve TAFI nin Yeri, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-597, 2002-2006 6. Küçük hücreli dışı akciğer kanserli hastalarda serum vasküler endotelial growtn faktör (VEGF) ve platelet faktör 4 düzeylerinin hastalık yanıtı ve sağ kalıma etkisi, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-847, 2007-7. Akut koroner sendrom olgularında yapışkan trombosit sendromunun rolü, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-737, 2004-2007 8. Dahili yoğun bakım hastalarıdsa periferik kanda eritronblastrların varlığının gösterilmei ve yaşam süresine etkisi, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-2009 Proje Araştırmacısı 1. Kırklareli İl Genelinde Sağlıklı Populasyonda Kan Sayım Parametrelerinin Saptanması, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-181, 1998 2. Edirne İlinde Sağlıklı Populasyonda Aktive Protein C Direnci ve FV Leiden Taraması, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP 224, 1999 3. Tekirdağ İl Genelinde Sağlıklı Populasyonda Kan Sayım Parametrelerinin Saptanması, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP 284, 1999 4. Edirne İlinde Haptoglobin Tiplerinin Dağılımı, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP 288, 1999 5. Hipotiroidik hastalarda tedavi öncesi ve sonrası trombin ile aktive edilebilen fibirnolitik inhibitör antijen düzeyi, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-779, 2004-2007 6. Anstabil angina pektoris ve non-q miyokard infarktüslü hastalarda C-RP, İnterlökin 6, neopterin ve fibronektinin prognostik değeri ve koroner arter tutulumu ilişkisi Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-584, 2004-2007 10
7. Akut koroner sendrom ve stabil angina pektorisli hastalarda osteoprotegrin düzeyleri ile koroner arter hastalığının yaygınlığı ve geç dönem prognozları arasındaki ilişki, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-776, 2004-2007 8. Anemisi olan ve olmayan kalp yetersizlikli hastalarda, levosimendan ın proinflamatuvar belirteçler, beyin natriuretik peptit ve matriks metaloproteinazlar üzerine etkinliğinin araştırılması, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP- 772, 2004-2007 9. Romatizmal valvüler kalp hastalığında dolaşan adezyon molekülleri düzeyi ile patojenik mekanizma arasındaki ilişki, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-510, 2004-2007 10. Diabetik nefropatili (evre III, IV,V) hastalarda osteoprotegrin ve reseptör aktivatör nükleer kappa B ligand, Trakya Üniv. Bilimsel Araştırma Projesi, TÜBAP-75, 2008 11. Trombozlu olgularda plazminojen eksikliği ve plazminojen geninindeki değişimlerin araştırılması, Ankara Üniversitesi Biyoteknoloji Enistütüsü Araştırma Projesi, Demir, B, Demir M, Bozdağ H, Akar N. 2009-12. Gas-6 proteininin megakaryopoezdeki rolü. Bingöl- Akpınar Ö, Uras F, Demir M. Trakya Üniversitesi ve Marmara Üniversitesi İş birliği ile Türk Hematoloji Derneği Araştırma Projesi 2009-2012 11
Uluslararası Hakemli Dergilerdeki Yayınlar 1. Görgülü A, Yalnız E, Demir M, Çobanoğlu S. Immunoglobulin concentration in human intervertebral disc herniations. Neuro- Orthopedics 1999; 26:41-48. 2. Demir M, Vural Ö, Yorulmaz F, Özer H. Prevalence of β thalassemia trait in Turkey. Haema 1999; 2(3):135-138 (SCI, SCI-E tarafından taranmayan dergi) 3. Demir M, Vural Ö, Sunar H, Altun A, Yorulmaz F, Özbay G. The prevalence of hereditary thrombophilia in the Trakya region of Turkey. Yonsei Med J 2000; 41(4):436-440. 4. Demir M, Çakır B, Vural Ö, Karakaş HM, Kara M, Çiçin İ. Staphylococcal pyomyositis in a patient with non-hodgkin s lymphoma. Ann Hematol 2000; 79:279-282. 5. Gerbutavisius R, Iqbal O, Messmore H, Hoppensteadt D, Demir M, Khan E, Bacher P, Fareed J. Differential effects of unfractionated heparin and low molecular weight heparins on tissue thromboplastin inhibition test. Clin Applied Thromb/Hemost 2000; 6(4):190-196. 6. Demir M, Iqbal O, Dietrich CP, Hoppensteadt DA, Ahmad S, Daud AN, Fareed J. Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I. Clin Appl Thrombosis/Hemostasis 2001; 7(1):44-52. 7. Demir M, Iqbal O, Untch B, Hoppensteadt DA, Gaikwad BS, Fareed J. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques. Clin/Appl Thrombosis/Hemostasis 2001; 7(1):38-43. 8. Demir M, Iqbal O, Hoppensteadt DA, Piccolo P, Ahmad S, Schultz CL, Linhardt RJ, Fareed J. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thrombosis/Hemostasis 2001; 7(2):131-140. 9. Piccolo P, Iqbal O, Demir M, Ma Q, Gerbutavicius R, Fareed J. Global anticoagulant effects of a novel sulfated pentomanan oligosaccharide mixture. Clin Appl Thrombosis/Hemostasis 2001; 7(2):149-152. 10. Çermik TF, Yüksel M, Demir M, Özyılmaz F, Kaya M, Vural Ö, Berkarda Ş. Bone metastasis from primary splenic angiosarcoma to the sacrum demonstrated by Tc-99m-labelled red blood cell and Tc- 99m MDP bone scintigraphy. Clin Nuclear Med 2001; 26(4):363-364. 11. Karakaş HM, Demir M, Özyılmaz F, Çakır B. Primary angiosarcoma of the spleen: in vivo and in vitro MRI findings. Clinical Imaging 2001; 25(3):192-196. 12. Gerbutavisius R, Fareed J, Messmore HL, Iqbal Q, Wehrmacher WH, Hoppensteadt DA, Demir M, Piccolo P, Ahmad S, Ma Q, Griniute R. Reference ranges of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited. Clin Appl Thromb Hemost 2002; 8(1):51-59. 13. Vatansever U, Acunas B, Demir M, Karasalihoğlu S, Erkuklu G, Şener S, Pala Ö. Nucleated red blood cell counts and erythropoietin levels in high risk neonates. Pediatrics Int 2002; 44(6):590-595. 12
14. Turgut B, Vural Ö, Demir M, Kaldır M. Candida arthritis in a patient with chronic myelogenous leukemia (CML) in blastic transformation, unresponsive to fluconazole, but treated effectively with liposomal amphotericin B. Ann Hematol 2002; 81(9):529-531. 15. Pamuk GE, Turgut B, Vural Ö, Demir M, Hatipoğlu O, Ünlü E, Altaner Ş, Gerenli M, Çakır B. Pulmonary alveolar proteinosis in a patient wit acute lymphoid luekemia regression after G-CSF therapy. Leuk Lymphoma 2003; 44:871-874. 16. Pamuk GE, Turgut B, Vural Ö, Demir M, Tek M, Altaner S. Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy. Clin Lab Haematol 2003; 25(5):329-331. 17. Pamuk GE, Turgut B, Vural Ö, Demir M, Soy M, Bozkurt B, Çelik H. Thrombosis in systemic lupus erythematosus: effect of inherited thrombophilic mutations. Clin Rheumatol 2003; 22(4-5):336-338. 18. Turgut B, Pamuk GE, Vural O, Demir M, Unlu E, Celik H, Cakir B, Kutlu K. An interesting presentation of intrathoracic extramedullary hematopoiesis in a patient with thalassemia intermedia. Clin Lab Haematol 2003; 25 (6):409-412. 19. Oz Puyan F, Bilgi S, Unlu E, Yalcin O, Altaner S, Demir M, Cakir B. Inflammatory pseudotumor of the spleen with EBV positivity: report of a case. Eur J Haematol 2004; 72(4):285-291. 20. Messmore HL, Coyne E, Wehrmacher WH, Demir AM, Fareed J. Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review. Curr Pharm Des 2004; 10:1001-1010. 21. Maddineni J, Ma Q, Hoppensteadt DA, Demir M, Manoni M, Cornelli U, Fareed J. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan. Clin Appl Thromb Hemost 2004; 10(1):27-37. 22. Gul C, Kurum T, Demir M, Ozbay G, Vural O, Iqbal O, Fareed J. Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor. Clin Appl Thromb Hemost 2004; 10(1):77-79. 23. Ravindranath TM, Gotto M, Demir M, Tobu M, Kujawski MF, Hoppensteadt DA, Samote V, Iqbal O, Sayeed MM, Fareed J. Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats. Clin Appl Thromb Hemost 2004; 10(1):379-385. 24. Iqbal O, Tobu M, Aziz S, Gerdisch M, Da Valle M, Demir M, Hoppensteadt DA, Ahmad S, Walenga JM, Fareed J.Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. J Card Surg 2005; 20(1):42-51. 25. Duran R, Biner B, Demir M, Çeltik C, Karasalihoğlu S. Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke. Clin Appl Thromb Hemost 2005; 11(1) :83-88. 26. Guldiken S, Demir M, Turgut B, Ugur-Altun B, Arikan E, Kara M. Global fibrinolytic capacity in patients with subclinical hypothyroidism. Endocrine J 2005; 52(3):363-367. 13
27. Turgut B, Vural Ö, Pamuk GE, Demir M, Yetişyiğit T. A patient with Fanconi anemia who presented with isolated thrombocytopenia at older age. Haema 2005; 8(3):479-480. (SCI, SCI-E tarafından taranmayan dergi) 28. Cetin M, Buyukberber S, Demir M, Sari I, Deniz K, Eser B, Altuntas F, Camci C, Ozturk A, Turgut B, Vural O, Unal A. Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. Am J Hematol 2005; 80(3):169-173. 29. Pamuk GE, Donmez S, Turgut B, Demir M, Vural Ö. Rituximabinduced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 2005; 78(1):81-81. 30. Turgut N, Akdemir O, Turgut B, Demir M, Ekuklu G, Vural O, Özbay G, Utku U. Hypercoagulopathy in stroke patients with nonvalvular atrial fibrillation: hematological and caridiological investigations. Clin Appl Thromb Hemost 2006; 12(1):15-20. 31. Guldiken S, Turgut B, Demir M, Arikan E, Kara M, Vural O, Tugrul A, Fareed J. The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus. Clin Appl Thromb Hemost 2006; 12(1):55-60. 32. Duran R, Biner B, Demir M, Celtik C, Karasalihoglu S, Acunas B. Factor V Leiden mutation, deficiency of antithrombin III and elevation of factor VIII in a child with ischemic stroke: a case report. Brain Dev 2006; 28(9):604-606. 33. Celik Y, Turgut N, Turgut B, Pamuk GE, Demir M. Chronic idiopathic demyelinating polyneuropathy (CIDP) associated with Kaposi's sarcoma. J Neurooncol 2006; 79:323-324. 34. Pamuk GE, Demir M, Orum H, Turgut B, Ozyilmaz F, Tekgunduz E. Secondary amyloidosis causing nephrotic syndrome in a patient with non-hodgkin s lymphoma: quite a rare diagnosis. Clin Lab Haematol 2006; 28:259-261. 35. Pamuk GE, Turgut B, Demir M, Tezcan F, Vural O. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia. Am J Hematol 2006; 81:631-633. 36. Turgut B, Turgut N, Akpinar S, Balci K, Pamuk GE, Tekgunduz E, Demir M. Dorsal sural nerve conduction study in vitamin B12 deficiency with megaloblastic anemia. J Peripher Nerv Syst 2006; 11:247-252. 37. Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: A Comparative Study. Am J Hematol 2006; 81:753-759. 38. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 2006; 28:241-244. 39. Pamuk GE, Turgut B, Demir M, Vural O. Increased adiponectin level in non-hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome. J Exp Clin Cancer Res 2006; 25:207-211. 14
40. Guldiken S, Karadag H, Demir M, Arikan E, Kara M. Plasma levels of asymmetric dimethylarginine and total homocysteine in first degree relatives of type 2 diabetic patients. Trakya Univ Tip Fak Derg 2007; 24(1):17-22. 41. Pamuk GE, Uyanik MS, Demir M, Tekgunduz E, Turgut B, Soy M. Systemic antineutrophil cytoplasmic antibody vasculitis in a patient with chronic lymphocytic leukemia Quite a rare diagnosis. Leuk Res 2007; 31(8):1149-1151. 42. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 2007; 119(1):79-84. 43. Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakır N. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinolysis 2007; 18(4):297-302. 44. Pamuk GE, Kundak T, Turgut B, Demir M, Vural O. Cutaneous Kaposi sarcoma which developed in a patient with aplastic anaemia using immunosuppressive therapy-description of the first adult case. Ann Acad Med Singapore. 2007; 36(3):211-212 45. Turgut B, Vural O, Pala FS, Pamuk GE, Tabakcioglu K, Demir M, Ongoren S, Soysal T, Algunes C. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma 2007; 48(2):311-320. 46. Demir M, Duran E, Yıgıtbası O, Vural O, Kurum T, Yuksel M, Turgut B, Walenga JM, Fareed J. Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Clin Appl Thromb Hemost 2007; 13(3):279-284. 47. Biner B, Devecioglu O, Demir M. Pitfalls in the diagnosis of immune thrombocytopenic purpura in children: 4 case reports. Clin Applied Thromb Hemost 2007; 13(3):329-333. 48. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 2007; 120(4):511-516. 49. Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, Hatiopoglu ON, Caglar T. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol 2007; 19(7):494-498. 50. Duran R, Biner B, Demir M. Factor VIII levels in children with ischemic stroke. Clin Applied Thromb Hemost 2007; 13(3):334-335. 51. Pamuk GE, Donmez S, Yesil Y, Tekgunduz E, Turgut B, Demir M. The evaluation of Kaposi sarcoma patients diagnosed at a single center. Türkiye Klinikleri Tıp Bilimleri Dergisi 2007; 27(5):658-663. 52. Tarighi B, Kurum T, Demir M, Azcan SN. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients. Can J Cardiol 2007; 23(8):651-655. 15
53. Guldiken B, Guldiken S, Demir M, Turgut N, Tugrul A. Low leptin levels in migraine: a case control study. Headache 2008; 48(7):1103-1107. 54. Gürlü VP, Demir M, Alimgil ML, Erda S. Systemic and topical freshfrozen plasma treatment in a newborn with ligneous conjunctivitis. Cornea 2008; 27(4):501-503. Reply Cornea 2009; 28(1):123-123. Gurlu VP, Demir M. Fresh Frozen Plasma Treatment of Ligneous Conjunctivitis: Use of Heparin and Allogeneic Serum Reply. 55. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke. Angiology 2008; 59(2):224-229. 56. Pamuk GE, Harmandar F, Ermantas N, Harmandar O, Turgut B, Demir M, Vural O. EORTC QLQ-C30 assessment in Turkish patients with hematologic malignancies: association with anxiety and depression. Ann Hematol 2008; 87(4):305-310. 57. Demir M, Tekgunduz E. Preoperative hemostatic evaluation: Scientific letter. Türkiye Klinikleri Tıp Bilimleri Dergisi 2008; 28(3):361-368. 58. Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related subclinical atherosclerosis? Platelets 2008; 19(2):146-154. 59. Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Chaining trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Int Angiol 2008; 27(3):176-192. 60. Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008; 34(1):58-73. 61. Guldiken S, Demir M, Arikan E, Azcan S, Tugrul A. Levels of highsensitivity C-reactive protein, leptin, and resistin in patients with overt hypothyroidism and subclinical hypothyroidism. The Endocrinologyst 2008; 18(1):30-33. 62. Guldiken B, Guldiken S, Demir M, Turgut N, Kabayel L, Ozkan H, Ozcelik E, Tugrul A.Insulin resistance and high sensitivity C-reactive protein in migraine. Can J Neurol Sci 2008; 35(4):448-451. 63. Ozcelik F, Erdogan O, Aktoz M, Ekuklu G, Tatli E, Demir M. Diagnostic value of plasma fibronectin level in predicting the presence and severity of coronary artery disease. Ann Hematol 2009; 88(3):249-253. 64. Pamuk GE, Aydogdu E, Turgut B, Demir M. The simultaneous diagnosis of Kaposi sarcoma and MDS RAEB-II in a human immunodeficiency virus-negative patient: A rare occurrence. Ann Hematol 2009; 88(4):389-391. 65. Pamuk GE, Pamuk ON, Umit EG, Puyan FO, Oztürk E, Demir M. Antineutrophil cytoplasmic antibody associated vasculitis in one patient with severe aplastic anemia Description of the first case. Leuk Res 2009; 33(8):e95-97. 66. Umit H, Unsal G, Tezel A, Soylu AR, Pamuk GE, Turgut B, Demir M, Tucer D, Ermantas N, Cevikbas U.Vanishing bile duct syndrome 16
in a patient with Hodgkin's lymphoma and asymptomatic hepatitis B virus infection. Acta Gastroenterol Belg 2009; 72(2):277-278. 67. Duran R, Vatansever U, Acunaş B, Orhaner B, Demir M. Transient leukoerythroblastosis in a very low birth weight infant with parvovirus B19 infection. Int J Infect Dis 2009; 13(6):e473-475. 68. Guldiken B, Demir M, Guldiken S, Turgut N, Ozkan H, Kabayel L, Tugrul A. Asymmetric dimethylarginine and nitric oxide levels in migraine during the interictal period. J Clin Neurosci 2009; 16(5):672-674. 69. Pamuk GE, Nuri Pamuk O, Orüm H, Arican O, Turgut B, Demir M. Elevated platelet-monocyte complexes in patients with psoriatic arthritis. Platelets 2009; 20(7):493-497. 70. Demir M, Tekgunduz E, Edis M, Duran E, Kurum T, Yigitbaşı Ö, Yüksel M. Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients. Turk J Hematol 2009; 26:171-175. 71. Taşkıran B, Guldiken S, Demir M, Kılıç Okman T. Soluble endothelial protein C receptor level in obesity. Obesity and Metabolism 2009; 5:134-138. 72. Tekgunduz E, Akpınar S, Öztürk E, Pamuk GE, Turgut B, Demir M. Is fondaparinux an effective alternative anticoagulant in patients with heparin induced thrombocytopenia type II? A case report and review of the literature. Trakya Univ Tip Fak Derg 2009; 26(2):166-172. 73. Pamuk GE, Nuri Pamuk O, Orüm H, Arican O, Turgut B, Demir M. Elevated platelet-monocyte complexes in patients with psoriatic arthritis. Platelets 2009; 20(7):493-497. 74. Adiguzel C, Iqbal O, Demir M, Fareed J. European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Clin Appl Thromb Hemost 2009; 15(6):645-651. 75. Varol FG, Ozgen L, Sayin C, Demir M. Correlation between maternal plasma thrombomodulin and infant birth weight in hypertensive disorders of pregnancy. Clin Appl Thromb Hemost 2009; 15(2):166-170. 76. Pamuk GE, Puyan FO, Ünlü E, Oztürk E, Demir M. The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: Description of an unreported complication. Leuk Res 2009; 33(6):864-867. 77. Guldiken B, Demir M, Guldiken S, Turgut N, Turgut B, Tugrul A. Oxidative stress and total antioxidant capacity in diabetic and nondiabetic acute ischemic stroke patients. Clin Appl Thromb Hemost 2009; 15(6):695-700. 78. Agirbasli M, Baykan OA, Tekin A, Sengor F, Cincin AA, Demir M, Vaughan DE. Short term effects of GnRH agonists on plasma fibirnolytic balance in patients with advanced prostate cancer. J Thromb Thrombolysis 2009; 27(2):172-174. 79. Pamuk GE, Taşçi M, Oztürk E, Demir M. Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VIIa: Report 17
on one case and review of other uses in acute leukemias. Med Oncol 2010; 27(1):16-19. 80. Tekgunduz E, Ozturk E, Pamuk GE, Turgut B, Puyan FO, Demir M. Testicular Plasmacytoma: Case Report. Turkiye Klinikleri Tip Bilimleri Dergisi 2010; 30(1):430-434. 81. Tekgunduz E, Demir M, Akpinar S. Acute Lymphoblastic Leukemia; Prognostic Factors' Perspective. UHOD-Uluslararasi Hematoloji- Onkoloji Dergisi 2010; 20(1):57-66. 82. Ermantas N, Guldiken S, Demir M, Tugrul A. Thrombin -Activatable Fibrinolysis Inhibitor (TAFI) Antigen and Activity Assay in Patients With Primary Hypothyroidism. Clin Appl Thromb Hemost 2010; 16(5)-568-573. 83. Tetik S, Kaya K, Demir M, Eksioglu-Demiralp E, Yardimci T. Oxidative Modification of Fibrinogen Affects Its Binding Activity to Glycoprotein (GP) IIb/IIIa. Clin Appl Thromb Hemost 2010; 16(1):51-59. 84. Sezer A, Tuncbilek N, Gultiken S, Demir M, Irfanoglu ME, Ibis C. The Risk of Venous Thromboembolism in Thyroid Surgery. The Endocrinologist 2010; 20(5):236-239. 85. Aktoz T, Aktoz M, Tatlı E, Kaplan M, Turan FN, Barutcu A, Atakan IH, Demir M, Altun A. Assessment of the relationship between asymmetric dimethylarginine and severity of erectile dysfunction and coronary artery disease. Int Urol Nephrol 2010; 42(4):873-879. 86. Aktoz M, Aktoz T, Tatli E, Kaplan M, Turan FN, Barutcu A, Atakan IH, Demir M, Altun A. Asymmetrical dimethylarginine and severity of erectile dysfunction and their impact on cardiovascular events in patients with acute coronary syndrome. Archives of Medical Science 2010; 6(2):168-175. 87. Edis EC, Hatipoǧlu ON, Yilmam I, Eker A, Tansel Ö, Süt N, Tekgündüz E, Demir M. Hospital-acquired pneumonia in patients receiving immunosuppressive therapy. Turk J Hematol 2010; 27(1):20-24. 88. Pamuk GE, Pamuk ÖN, Örüm H, Demir M, Turgut B, Çakir N. Might platelet-leucocyte complexes be playing a role in major vascular involvement of Behçet's disease? A comparative study. Blood Coagul Fibrinol 2010; 21(2):113-117. 89. Saatci C, Caglayan AO, Kocyigit I, Akalin H, Kaynar LG, Altuntas F, Eser B, Demir M, Cetin M, Ozkul Y. Expression of WT1 gene in multiple myeloma patients at diagnosis: Is WT1 gene expression a useful marker in multiple myeloma? Hematology 2010; 15(1):39-42. 90. Demir M, Tekgündüz E. Antithrombotic and Anticoagulant Usage Policies. Trakya Univ Tip Fak Derg 2010; 27(1):69-73. 91. Taskiran B, Guldiken S, Demir AM, Okman TK, Arikan E, Turgut B, Tugrul AA. Effect of obesity on TAFI in postmenopausal period. Obesity Res Clin Practice 2010;4:e271-e276 92. Kaygusuz I, Firatli-Tuglular T, Toptas T, Ugurel V, Demir M. Low Levels of Protein Z Are Associated With HELLP Syndrome and its Severity. Clin Appl Thromb Hemost 2011; 17(2):214-219. 93. Guldiken S, Guldiken B, Demir M, Kabayel L, Ozkan H, Turgut N, Hunkar R, Kat S. Soluble CD40 ligand and prolactin levels in 18
migraine patients during interictal period. J Headache Pain 2011; 12(3):355-360. 94. Turgut B, Turgut N, Celik Y, Tekgündüz E, Pamuk GE, Demir M. Differences in platelet-leukocyte aggregates among subtypes of acute cerebral ischemia. J Neurol Sci 2011; 305(1-2):126-130. 95. Düzen B, Taş A, Demir M, Usta U, Yağız R, Koten M, Karasalihoğlu A. Effect of the levels of vascular endothelial growth factor-a and C on the prognosis of patients with larynx carcinoma. Kulak Burun Bogaz Ihtis Derg 2011; 21(3):122-128. 96. Sener A, Enc E, Ozsavci D, Vanizor-Kural B, Yanikkaya-Demirel G, Oba R, Uras F, Demir M. Exogenous l-arginine and HDL can alter LDL and ox-ldl-mediated platelet activation: Using platelet P- selectin receptor numbers. Clin Appl Thromb/Hemost 2011; 17(6): E79-86 97. Orüm H, Pamuk GE, Pamuk ON, Demir M, Turgut B. Does anti-tnf therapy cause any change in platelet activation in ankylosing spondylitis patients? : A comparative study. J Thromb Thrombolysis 2012; 33(2):154-159. 98. Tezel A, Demir M. Infalmmarory bowel disease and thrombosis. Turkish J Hematol 2012;29(2):111-119 99. Taskiran B, Altun BU, Vardar SA, Demir AM, Karadağ CH, Altun A. Effect of exercise on ADMA level in type 2 diabetes mellitus. Balkan Med J. 2012;1:62-67 100. Tokgoz H, Caliskan U, Demir M. Successful use of fondaparinux in a child with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2012;23(8):769-71. doi: 10.1097/MBC.0b013e328358afc9. 101. Ekiz Bilir B, Soysal Atile N, Kirkizlar O, Kömürcü Y, Akpinar S, Sezer A, Demir M, Hekimoğlu S. Effectiveness of preoperative plasmapheresis in a pregnancy complicated by hyperthyroidism and anti-thyroid drug-associated angioedema. Gynecol Endocrinol. 2013 Feb 6. [Epub ahead of print] 102. Tekgündüz E, Demir M, Akyol-Erikçi A, Akpınar S, Öztürk E, Kırkızlar O. Sticky platelet syndrome in patients with uninduced venous thrombosis. Turk J Hematol 2013;30:48-52 103. Sahin F, Saydam G, Cömert M, Uz B, Yavuz AS, Turan E, Yönal I, Atay H, Keltikli E, Turgut M, Pehlivan M, Akay MO, Gürkan E, Paydaş S, Kahraman S, Demirkan F, Kırkızlar O, Akpınar S, Pamuk GE, Demir M, Ozbaş HM, Sönmez M, Gültürk M, Salihoğlu A, Eşkazan AE, Ar C, Haydaroğlu Şahin H, Ongören S, Başlar Z, Aydın Y, Yenere MN, Tüzüner N, Ferhanoğlu B, Haznedaroglu IC, Ilhan O, Soysal T. Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turk J Haematol. 2013 Dec;30(4):351-8 104. Özakpınar ÖB, Maurer AM, Adıgüzel C, Çilingir ÖT, Demir M, Uras F. Periferik kandan izole edilen hematopoietik kök hücrelerin megakaryosite farklılaşması. Turk J Biochemistry 2013;38(3):243-248. 19
105. Umit EG, Umit HC, Kuloğlu F, Demir AM. Multiple Liver and Muscle Abscesses and Sepsis with Bacillus pantothenticus in a Leukemia Patient. Turk J Haematol. 2014;31(3):319-320. 106. Akan H, Ongören Aydın S, Saltoğlu N, Cağatay A, Akalın H, Arat M, Ali R, Kalayoğlu-Beşışık S, Demir AM. Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1). Turk J Haematol. 2014;31(2):111-20. 107. Pamuk GE, Ak R, Tasci M, Harmandar F, Demir M, Arican O. Clinical characteristics of haematological malignancy patients diagnosed with leukaemia cutis: Experience of a single centre. Australas J Dermatol. 2015 May;56(2):116-9 108. Akseki TH, Vardar SA, Demir M, Palabıyık O, Karaca A, Guksu Z, Ortanca A, Süt N. The alteration of NTproCNP plasma levels following anaerobic exercise in physically active young men. Anatol J Cardiol. 2015;15(2):97-102. 109. Koylu A, Pamuk GE, Uyanik MS, Demir M, Pamuk ON. Immune thrombocytopenia: epidemiological and clinical features of 216 patients in northwestern Turkey. Ann Hematol. 2015;94(3):459-66. 110. Uras F, Küçük B, Bingöl-Özakpınar Ö, Demir AM. Growth Arrest- Specific 6 (Gas6) and TAM Receptors in Mouse Platelets. Turk J Hematol 2015, doi: 10.4274/tjh.2013.0097, pp 58-63 111. Uyanik MS, Mehmet Baysal, Gulsum Emel Pamuk, Muhammet Maden, Mustafa Akker, Elif Gulsum Umit, Demir M, Erkan Aydogdu. Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms? Indian Journal of Hematology and Blood Transfusion 08/2015; DOI: 10.1007/s12288-015-0578-2. Uluslararası bilimsel toplantılarda sunulan ve Bildiri kitabında basılan bildiriler 1. Dinçer E, Demir M, Ferhanoğlu B, Başlar Z, Soysal T, Aydın Y, Ülkü B, Aktuğlu G, Akman N. Results of an intensive chemotherapy protocol (BFM) in adult ALL. Turk J Haematol 1995;14(Suppl 1):828. 2. Demir M, Başlar Z, Soysal T, Ferhanoğlu B, Aydın Y, Ülkü B, Aktuğlu G, Akman N. Mitoxantrone, etoposide, intermediated dose ara-c combination chemotherapy protocol in resistant or recurrent AML. Turk J Haematol 1995;14(Suppl 1):868. 3. Ferhanoğlu B, Türemen E, Demir M, Soysal T, Altınkaya N, Ilıkkan B, Özkan F. Acute leukemia and pregnancy and autopsy findings of a premature baby. Turk J Haematol 1995;14(Suppl 1):871. 4. Eralp Y, Ferhanoğlu B, Demir M, Hız M, Tüzüner N, Akman N, Türümen E. Primary lymphoma of bone. Turk J Haematol 1995;14(Suppl 1):904. 20
5. Vural Ö, Saltık A, Demir M, Akar N, Arcasoy A. A screening of β thalassemia trait and the frequency of hemoglobinopathies in Edirne- Türkiye. Int J Haematol 1996;64(Suppl 1):313. 6. Demir M, Vural Ö, Sunar H, Altun A, Yorulmaz F, Özbay G. Natural inhibitors and resistance to activated protein C in venous and arterial thrombosis. Haemostasis 1998;28(Suppl 2):572. 7. Yılmaz T, Demir M, Vural Ö, Bilgi S. The effect of captopril on development of the experimental atherosclerosis in rabbits. Haemostasis 1998;28(Suppl 2):336. 8. Memiş D, Demir M, Özden A, Pamukçu Z, Vural Ö. Pentoxifylline infusion in sepsis patients in ICU. 11 th International Intensive Care Symposium, İstanbul, May 14-15,1999. 9. Uras F, Hoppensteadt DA, Demir M, Messmore H, Leya F, Fareed J. Elevated D-dimer and P-selectin levels as markers of acute coronary syndrome. Clin Chemist 2000;46(S6):514. 10. Iqbal O, Demir M, Hoppensteadt DA, Fareed J. Ecarin clotting time is sensitive to heparinoids: diagnostic and clinical implication. Inter Angiol 2000;19(Suppl 1):95. 11. Fareed J, Jeske WP, Walenga JM, Hoppensteadt DA, Uras F, Demir M. Prolonged use of low molecular weight heparin after PTCA results in a down regulation of C-reactive protein and von Willebrand factor. Clin Chemist 2000;46(S6):93. 12. Kalkounos P, Hoppensteadt DA, Demir M, Fareed J. Comparative pharmacodynamics of ReoPro and a humanized Fab fragment derived GP IIb/IIIa antibody YM 337. FASEB J 2000;14(8):A1418. 13. Demir M, Dietrich CP, Nader H, Iqbal O, Hoppensteadt DA, Ma Q, Fareed J. Anticoagulant and antiprotease effects of shrimp (Penaeus brasiliensis) heparin and its neutralization by heparinase I. FASEB J 2000;14(8):A1415. 14. Iqbal O, Gerbutavicius R, Messmore H, Hoppensteadt DA, Demir M, Khan E, Fareed J. Differential effects of heparins on tissue thromboplastin inhibition test. Fibrinol Proteol 2000;14(Suppl 1):49. 15. Walenga JM, Hoppensteadt DA, Cella G, Demir M, Fareed J. Fibrinolytic deficit in heparin-induced thrombocytopenic syndrome: laboratory and clinical implications. Fibrinol Proteol 2000;14(Suppl 1):61. 16. Iqbal O, Gerdisch MW, DaValle MJ, Demir M, Walenga JM, Fareed J, Aziz S, Bakhos M. Successful use of recombinant hirudin for anticoagulation and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing cardiac bypass surgery. Cardiovascular Engineering 2000;5:151. 17. Demir M, Iqbal O, Hoppensteadt DA, Mousa S, Fareed J. Comparative anticoagulant effects of tinzaparin as studied in clot based assays. Int J Hematol 2000;72:85. 18. Iqbal O, Demir M, Hoppensteadt DA, Walenga JM, Fareed J. A methylated pentasaccharide analog resists neutralization by heparinase. Int J Hematol 2000;72:80. 19. Demir M, Fareed J, Iqbal O, Hoppensteadt DA, Leya F, Lewis B, Kereiakes D. Low molecular weight heparins as anticoagulants for 21
percutaneous intervention: pharmacokinetic and pharmacodynamic considerations. J Clin Pharmacol 2000;40(9):80. 20. Hoppensteadt DA, Argenti DP, Demir M, Iqbal O, Fareed J. Differential pharmacokinetics of enoxaparin in normal volunteers of ideal body weight 80-100% and greater than or equal to 130% of ideal body weight. J Clin Pharmacol 2000;40(9):78. 21. Fareed J, Hoppensteadt DA, Jeske WP, Ma Q, Demir M. Enoxaparin levels calculated by using circulating amidolytic anti-xa assay do not reflect the true pharmacodynamic response after intravenous administration: Clinical implication Kardiologie 2000;89:891. 22. Ahmad S, Demir M, Walenga JM, Hoppensteadt DA, Bianchini P, Venuti R, Ward DP, Fareed J. Repeated administration of an ultra low molecular weight heparin, OP2000, at high dosage does not result in thrombocytopenia despite the generation of anti-heparin-pf4 antibodies. Blood 2000;96(11):2699. 23. Fareed J, Ahmad S, Walenga JM, Hoppensteadt DA, Jeske WP, Demir M, Mousa SA, Bakhos M. Elevated plasma levels of inflammatory markers in heparin-induced thrombocytopenia. Blood 2000;96(11):4088. 24. Fareed J, Ahmad S, Walenga JM, Aldabbagh A, Jeske WP, Demir M, Bakhos M. Upregulation of immunoglobulins may be associated with the pathogenesis of heparin-induced thrombocytopenia. Blood 2000;96(11):3952. 25. Rizvi G, Lassen M, Demir M, Hoppensteadt DA, George M, Borris L, Iqbal O, Gerbutavicius R, Fareed J. Ex vivo studies on the pharmacodynamic effects of defibrotide in patients after a bridged intravenous/oral administration for the management of postorthopedic surgical prophylaxis of deep-vein thrombosis. Blood 2000;96(11):4116. 26. Demir M, Gaikwad BS, Iqbal O, Bano A, Shadid H, Gerbutavicius R, Ahmad S, Fareed J. Anti-Xa adjusted low molecular weight heparins exhibit wide assay-dependent variations: monitoring and dosing implications. Blood 2000;96(11):4082. 27. Demir M, Untch B, Iqbal O, Rizvi G, Podger D, Fareed J. Measurement of a novel synthetic anticoagulant oligosaccharide in normal human plasma by ecarin clotting time supplemented with heparin cofactor II. Blood 2000;96(11):4083. 28. Hering J, Pulia M, Schultz C, Jeske WP, Ma Q, Hoppensteadt DA, Demir M, Fareed J. Comparative pharmacokinetics and pharmacodynamics of tinzaparin and unfractionated heparin at a fixed dosage (75 U/kg) in Primates. Blood 2000 ; 96 (11) : 4099. 29. Yılmaz A, Demir M, Utku U, Vural Ö, Ekuklu G, Çelik Y, Turgut N. The relation of serum interleukin-6 levels with lesion size and prognosis in acute ischemic stroke. European J Neurol 2001;8(Suppl 2):84. 30. Ahmad S, Demir M, Walenga JM, Untch B, Hoppensteadt DA, Gaikwad BS, Venuti R, Ward DP, Fareed J. Sustained tissue factor pathway inhibitor release may contribute to the therapeutic effects of OP 2000 in inflammatory bowel disease. FASEB J 2001;15(4):A592. 22
31. Piccolo P, Cornelli U, Demir A, Ma Q, FareedJ. Anticoagulant effects of low molecular weight (<3000 Da) sulfated oligosaccharides of synthetic and natural origin. Abstarct: CD3237, XVIII. ISTH July 6-12, 2001, Paris, France. 32. Demir M, Hoppensteadt DA, Ma Q, Iqbal I, Podger D, Fareed J. In vitro anticogulant profile unique HC-II binding heparinomimetic (PI- 88). Abstarct:P1613, XVIII. ISTH July 6-12, 2001, Paris, France. 33. Shadid H, Daud A, Iqbal O, Ahmad S, Hoppensteadt DA, Demir M, Walenga JM, Fareed J. Neutralization of the anticoagulant and bleeding effects of an ultra-low molecular weight heparin (OP2000) by heparinase I: Clinical İmplications. Abstract: CD3552, XVIII. ISTH July 6-12, 2001, Paris, France. 34. Gerbutavicius R, Messmore H, Wehrmacher WH, Iqbal O, Hoppensteadt DA, Demir M, Fareed D. Reference intervals for the dilute thromboplastin inhibition test (DTTIT) and the dilute Russell s viper venom test (DRVVT) for lupus anticoagulant. Abstract: CD3559, XVIII. ISTH July 6-12, 2001, Paris, France. 35. Uğur-Altun B, Arıkan E, Demir M, Güldiken S, Tuğrul A, Hypercoagulability in patients with autoimmune hyperthyroidism. Abstracts of the 11 th Balkan Congress of Endocrinology, Turk J Endocrinol Metabol 2001;5(2)(Suppl):P8. 36. Özdil A, Doğanay L, Demir M, Oz Puyan F, Bilgi S. Detection of Epstein Barr Virus (EBV) in Hodgkin s disease in Thracian region of Turkey; by in situ hybridization. Virchow Archiv 2001;439(3):P470. 37. Iqbal O, Ahmad S, Lewis BE, Mousa Y, Demir M, Hoppensteadt DA, Fareed J. Monitoring of the anticoagulant effects of argatroban in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary interventions-the ARG 310 study. Clin Chemist 2001;47(S6): 554. 38. Demir M, Hoppensteadt DA, Mayuga M, Iqbal O, Piccolo P, Fareed J. A comparison of three different methods to measure chromogenic anti-xa levels. Clin Chemist 2001; 47(S6):524. 39. Walenga JM, Florian M, Hoppensteadt DA, Demir A, Leitz H, Jeske WP, Messmore HL, Leya F, Fareed J. Heparin, LMW heparins and HC II binding oligosaccharides, but not pentasaccharide regulate TAFI. Thromb Haemost 2001; (Suppl):2011. 40. Cicin I, Demir M, Vural O, Turgut B, Vurkun M. Distribution of haptoglobin subtypes in a Turkish population from Edirne (East- Trakya)-Turkey, 7 th Congress of European Hematology Association, 6-9 June 2002, Florence, Italy. 41. Turgut N, Akdemir O, Turgut B, Demir M, Ekuklu G, Vural Ö, Utku U, Özbay G. Hypercoagulability in patients with non-valvular atrial fibrillation: hematological and cardiological investigation. J Neurol 2003; 250 (suppl 2):P219. 42. Soylu AR, Bilgi S, Demir M, Dökmeci G, Ustundağ Y, Tezel A, Ümit H, Amuca H, Vural Ö, Türe M, Kutlu K. Predictive value of serum hyaluronic acid (HA) measurement for cirrhosis in patients with chronic liver disease (CLD). J Hepatol 2003; 38 (suppl 2):228. 43. Tobu M, Demir M, Iqbal Q, Leitz H, Hoppensteadt DA, Walenga JM, Fareed J. The irrelevance of international normalized ratio in the 23
monitoring of anti-iia and anti-xa drugs. J Thromb Haemost 2003;1(suppl 1):P1994. 44. Demir M, Iqbal Q, Schultz C, Ma Q, Hoppensteadt DA, Fareed J. Fibrinopeptide-A generation inhibition by anti-xa drugs and its correlation with activated clotting time. J Thromb Haemost 2003; 1(suppl 1):P2077. 45. Ahmad S, Schultz C, Hoppensteadt D, Iqbal O, Demir M, Fareed J. Investigations on the generation and functionality of PI-88 induced HIT-associated antibody subtypes in patients with malignant disorders. FASEB J 2004; 18(4):A197. 46. Iqbal Q, Tobu M, Demir MA, Hoppensteadt DA, Fareed J, Cort S, Deitcher S. Upregulation of monocyte chemotactic protein-1 and CD 40 ligand in cancer patients and their modulation by subcutaneous enoxaparin-results from the ONCENOX study. 2004 ASCO Annual Meeting, Abstract No: 6069. 47. Florian-Kujawski MR, Hoppensteadt DA, Iqbal Q, Demir M, Tobu M, Fareed D, Fareed J. Role of PAI-1 and TAFI in the mediation of fibrinolytic deficit in cancer patients. 2004 ASCO Annual Meeting, Abstract No: 9727. 48. Tobu M, Hoppensteadt DA, Cunanan J, Iqbal Q, Demir MA, Fareed J, Deitcher S. Hyperhomocysteinemia in cancer patients with thrombosis is independent of methylene tetrahydrofolate reductase gene mutation. 2004 ASCO Annual Meeting, Abstract No: 6152. 49. Fareed J, Fareed D, Bick R, Bacher P, Iqbal O, Tobu M, Hoppensteadt D, Demir M, Saxena R. Nitric oxide levels and its relevance to C- reactive protein, CD40L, TF and TNF-alfa in malignancy associated hypercoagulable state. Pathophysiol Haemost Thromb 2004:33 (suppl 2); OC025. 50. Guldiken S, Turgut B, Demir M, Arikan A, Kara M, Tugrul A, Vural O. The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus. Pathophysiol Haemost Thromb 2004:33 (suppl 2); OC032. 51. Turgut B, Guldiken S, Demir M, Ugur-Altun B, Gerenli M, Vural O, Tugrul A. Relationship between global fibrinolytic capacity and cardiovascular risk factors in obese patients. Pathophysiol Haemost Thromb 2004:33 (suppl 2); PO090. 52. Guldiken S, Demir M, Turgut B, Ugur-Altun B, Arikan E, Kara M. Global fibrinolytic capacity in patients with subclinical hypothyroidism. Turk J Endocrinol Metabolism 2004; 8(suppl 1):P205 (30 th Annual Meeting of European Thyroid Association). 53. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A. The levels of circulating markers of atherosclerosis and inflammation in patients with simple obesity: soluble CD40 ligand and high sensitive C-reactive protein. Obesity Reviews 2005;6(Suppl 1):P633. 54. Guldiken S, Kilic-Okman T, Demir M, Arikan E, Kucuk M. Is plasma level of von Willebrand Factor the predictor of endothelial dysfunction in women with polycystic ovary syndrome? Thromb Res 2005;115(Suppl 1): A118. 24